Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

TLDR: Notable survival, response, and time‐to‐progression data suggest that a bortezomib starting dose of 1·3’mg/m2 is preferred, and if bortzomib dose reduction is required, the 1·0 mg/ m2 dose still offers patients a substantial survival benefit.

Abstract: Summary The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1·0 and 1·3 mg/m2), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow-up (median >5 years). One- and 5-year survival rates were 82% and 32%, respectively, in the 1·0 mg/m2 group (n = 28), and 81% and 45%, respectively, in the 1·3 mg/m2 group (n = 26). Notable survival, response, and time-to-progression data suggest that a bortezomib starting dose of 1·3 mg/m2 is preferred. If bortezomib dose reduction is required, the 1·0 mg/m2 dose still offers patients a substantial survival benefit.